CST: 24/05/2016 22:19:40   

CORRECTION FROM SOURCE: Spectral Announces Fourth Quarter and Fiscal 2015 Results

55 Days ago

TORONTO, ONTARIO--(Marketwired - Mar 30, 2016) -

This document corrects and replaces the press release that was sent today at 8:00 a.m. The error occured in the 4th Paragraph in Financial Review where $14,048 should be $14,048,000. The complete and corrected version follows.

Spectral Medical Inc., (TSX:EDT) (OTCQX:EDTXF), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced its financial results for the fourth quarter and for the year ended December 31, 2015.

Financial Review

Revenue for the three months ended December 31, 2015 was $715,000 compared to $699,000 for the same three month period last year. Revenue for the year ended December 31, 2015 was $3,089,000 compared to $2,964,000 for the prior year, representing an increase of $125,000, or 4%.

For the quarter ended December 31, 2015, the Company reported operating costs of $3,130,000 compared to $3,195,000 for the corresponding period in 2014. Operating costs for the year ended December 31, 2015 amounted to $12,696,000 compared to $13,125,000 in 2014. Most of the Company's expenses are incurred in its Phase III clinical trial and will vary depending on the timing and level of patient enrolment. Apart from clinical trial activities, the Company continues to maintain a low cost operating structure for its base business operations.

Loss for the quarter ended December 31, 2015 was $2,400,000 ($0.01 per share) compared to $2,463,000 ($0.01 per share) for the same quarter last year. For the year ended December 31, 2015, the Company reported a loss of $9,524,000, ($0.05 per share), compared to a loss of $9,492,000 ($0.06 per share), for the year ended December 31, 2014.

The Company concluded the 2015 year with cash and cash equivalents of $6,369,000 compared to $10,054,000 cash and cash equivalents on hand as of December 31, 2014. After closing of its bought deal financing subsequent to the year end, the Company had $14,048,000 of cash to fund its operations.

The total number of shares outstanding for the Company was 190,771,405 as at December 31, 2015.

About Spectral

Spectral is a Phase III company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ ('PMX"). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream. Directed by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis. Spectral's EUPHRATES trial is the world's only active and most innovative Phase III study in the area of septic shock.

PMX has been approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 150,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. Approximately 350,000 patients are diagnosed with severe sepsis and septic shock in North America each year, representing a greater than $3 billion market opportunity for Spectral. Spectral is listed on the Toronto Stock Exchange under the symbol EDT, and on the OTCQX under the symbol EDTXF. For more information please visit www.spectraldx.com

Forward-looking statement

Information in this news release that is not current or historical factual information may constitute forward- looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.

Spectral Medical Inc.
Consolidated Statements of Financial Position
(in thousands of Canadian dollars)
December 31 December 31
2015 2014
$ $
Assets
Current assets
Cash 6,369 10,054
Trade and other receivables 630 583
Inventories 243 166
Prepayments and other assets 141 185
7,383 10,988
Non-current assets
Property and equipment 717 490
Intangible asset 359 384
1,076 874
Total assets 8,459 11,862
Liabilities
Current liabilities
Trade and other payables 2,850 2,893
Deferred revenue 176 149
Total liabilities 3,026 3,042
Equity
Share capital 53,058 46,879
Contributed surplus 7,849 7,849
Other equity reserves 3,723 3,542
Deficit (59,197 ) (49,450 )
Total equity 5,433 8,820
Total liabilities and equity 8,459 11,862
Spectral Medical Inc.
Consolidated Statements of Loss and Comprehensive Loss
For the years ended December 31, 2015 and 2014
(in thousands of Canadian dollars, except for share and per share data)
2015 2014
$ $
Revenue 3,089 2,964
Expenses
Changes in inventories of finished goods and work-in-process 199 310
Raw materials and consumables used 469 444
Employee benefits 3,600 3,460
Consulting and professional fees 6,112 6,584
Product development 16 273
Regulatory and investor relations 624 300
Travel and entertainment 976 989
Depreciation and amortization 172 205
Foreign exchange (gain) loss (12 ) 54
Other expenses 540 506
12,696 13,125
Operating loss (9,607 ) (10,161 )
Finance income 83 60
Loss and comprehensive loss before tax (9,524 ) (10,101 )
Deferred tax recovery - 609
Loss and comprehensive loss for the year (9,524 ) (9,492 )
Basic and diluted loss per common share (0.05 ) (0.06 )
Weighted average number of common shares outstanding 188,064,621 154,540,951
Spectral Medical Inc.
Consolidated Statements of Changes in Equity
For the years ended December 31, 2015 and 2014
(in thousands of Canadian dollars)

Issued capital
Contributed
surplus
Share-based
compensation

Warrants

Deficit

Total equity
Number $ $ $ $ $ $
Balance, January 1, 2014 134,462,561 33,957 3,864 3,239 4,594 (39,958 ) 5,696
Private placement 45,051,186 12,816 - - - - 12,816
Share options exercised 222,500 105 - (45 ) - - 60
Warrants exercised 994 1 - - - - 1
Warrants expiry, net of tax - - 3,985 - (4,594 ) - (609 )
Loss and comprehensive loss for the year - - - - - (9,492 ) (9,492 )
Share-based compensation - - - 348 - - 348
Balance, December 31, 2014 179,737,241 46,879 7,849 3,542 - (49,450 ) 8,820
Private placement 11,049,464 6,021 - - - - 6,021
Shares repurchased under NCIB (480,000 ) (132 ) - - - (223 ) (355 )
Share options exercised 464,700 290 - (124 ) - - 166
Loss and comprehensive loss for the year - - - - - (9,524 ) (9,524 )
Share-based compensation - - - 305 - - 305
Balance, December 31, 2015 190,771,405 53,058 7,849 3,723 - (59,197 ) 5,433
Spectral Medical Inc.
Consolidated Statements of Cash Flows
For the years ended December 31, 2015 and 2014
(in thousands of Canadian dollars)
2015 2014
$ $
Cash flow provided by (used in)
Operating activities
Loss and comprehensive loss for the year (9,524 ) (9,492 )
Adjustments for:
Depreciation on property and equipment 147 180
Amortization of intangible asset 25 25
Share-based compensation 305 348
Loss on disposal of property and equipment 7 1
Deferred tax recovery - (609 )
Changes in items of working capital :
Trade and other receivables (47 ) (14 )
Inventories (77 ) 149
Prepayments and other assets 44 104
Trade and other payables (43 ) (743 )
Deferred revenue 27 43
Net cash used in operating activities (9,136 ) (10,008 )
Investing activities
Property and equipment expenditures (403 ) (60 )
Proceeds on disposal of property and equipment 22 16
Net cash used in investing activities (381 ) (44 )
Financing activities
Private placement 6,021 12,816
Share options exercised 166 60
Shares repurchased under NCIB (355 ) -
Warrants exercised - 1
Net cash provided by financing activities 5,832 12,877
(Decrease) increase in cash (3,685 ) 2,825
Cash, beginning of year 10,054 7,229
Cash, end of year 6,369 10,054

Anthony Businskas
Executive Vice President and CFO
Spectral Medical Inc.
416-626-3233 ext. 2200
tbusinskas@spectraldx.com
Ali Mahdavi
Capital Markets & Investor Relations
416-962-3300
am@spinnakercmi.com